Celiac Disease
|
0.300 |
Biomarker
|
disease |
CTD_human |
Celiac disease biomarkers identified by transcriptome analysis of small intestinal biopsies.
|
30097691 |
2018 |
Intestinal Obstruction
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis.
|
22466613 |
2012 |
CYSTIC FIBROSIS MODIFIER 1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis.
|
22466613 |
2012 |
Inflammatory Bowel Diseases
|
0.200 |
Biomarker
|
group |
RGD |
Experimental colitis: decreased Octn2 and Atb0+ expression in rat colonocytes induces carnitine depletion that is reversible by carnitine-loaded liposomes.
|
17065219 |
2006 |
Sarcoma, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Stimulation of expression of the intestinal glutamine transporter ATB0 in tumor-bearing rats.
|
17006743 |
2006 |
Acidosis
|
0.200 |
Biomarker
|
phenotype |
RGD |
Stimulation of intestinal glutamine absorption in chronic metabolic acidosis.
|
15300171 |
2004 |
Cystic Fibrosis
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Among the most strongly down-regulated genes are the FXR targets Fgf15 and Nr0b2, the PPARα target Pdk4, and the PXR target Ces2a, whereas expression of the CF modifier gene Slc6a14 was strongly increased.
|
31251978 |
2020 |
Cystic Fibrosis
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Using CFBE41o cells, we showed that the positive SLC6A14 effect was mainly dependent on the nitric oxide (NO) synthase activity, nitrogen oxides, including NO, and phosphorylation by protein kinase G. These finding were confirmed in CF-HBE, as inducible NO synthase inhibition abrogated the functional interaction between SLC6A14 and pharmacological corrected F508del-CFTR.
|
31189070 |
2019 |
Cystic Fibrosis
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
The purpose of the current work was to determine the biological role of <i>Slc6a14,</i> by disrupting its expression in CF mice bearing the major mutation, F508del.
|
30004386 |
2018 |
Cystic Fibrosis
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Association of clinical severity of cystic fibrosis with variants in the SLC gene family (SLC6A14, SLC26A9, SLC11A1 and SLC9A3).
|
28756021 |
2017 |
Cystic Fibrosis
|
0.060 |
Biomarker
|
disease |
BEFREE |
Regions on chr3q29 (MUC4/MUC20; P=3.3 × 10(-11)), chr5p15.3 (SLC9A3; P=6.8 × 10(-12)), chr6p21.3 (HLA Class II; P=1.2 × 10(-8)) and chrXq22-q23 (AGTR2/SLC6A14; P=1.8 × 10(-9)) contain genes of high biological relevance to CF pathophysiology.
|
26417704 |
2015 |
Cystic Fibrosis
|
0.060 |
Biomarker
|
disease |
BEFREE |
We sought to determine whether SLC26A9, SLC9A3 and SLC6A14, that contribute to meconium ileus in CF, are pleiotropic for other early-affecting CF co-morbidities.
|
24057835 |
2014 |
Obesity
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, these data confirm an association of the SLC6A14 gene locus with obesity.
|
15331564 |
2004 |
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
The SLC6A14 gene is an interesting novel candidate for obesity because it encodes an amino acid transporter, which potentially regulates tryptophan availability for serotonin synthesis and thus possibly affects appetite control.
|
14660752 |
2003 |
Obesity
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Do allelic variants of SLC6A14 predispose to obesity?
|
14660737 |
2003 |
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Plasma membrane transporter SLC6A14 transports all neutral and basic amino acids in a Na/Cl - dependent way and it is up-regulated in many types of cancer.
|
31326539 |
2019 |
Lung diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Using the SS we integrated the lung disease association locus with eQTLs from nasal epithelia of 63 CF participants and demonstrated evidence of colocalization with airway-specific regulation of SLC6A14 (p = 2.3x10(-4)).
|
30807572 |
2019 |
Pancreatic carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Survival analysis of TCGA data and clinical data suggested that TMC7, TMPRSS4, SCEL, SLC2A1, CENPF, SERPINB5 and SLC6A14 can be potential biomarkers for the prognosis of PC.
|
30639415 |
2019 |
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Plasma membrane transporter SLC6A14 transports all neutral and basic amino acids in a Na/Cl - dependent way and it is up-regulated in many types of cancer.
|
31326539 |
2019 |
Pancreatic Ductal Adenocarcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Survival analysis unveiled that the high expression levels of SLC6A14, GALNT5 and TSPAN1 may correlate with the poor prognosis while high expression levels of IAPP may contribute to a better prognosis in patients with PAAD.
|
31731384 |
2019 |
Meconium ileus
|
0.020 |
Biomarker
|
disease |
BEFREE |
The associated modifier loci colocalized with expression quantitative trait loci (eQTLs) for ATP12A (p = 3.35x10(-8)), SLC6A14 (p = 1.12x10(-10)) and SLC26A9 (p = 4.48x10(-5)) in the pancreas, even though meconium ileus manifests in the intestine.
|
30807572 |
2019 |
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The present review primarily focuses on one particular amino acid transporter, SLC6A14 (also known as ATB<sup>0,+</sup>), with regard to its relevance to specific diseases, including cancer, and the molecular mechanisms underlying the disease-related alterations in the expression of the transporter.
|
29204754 |
2017 |
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
The present review primarily focuses on one particular amino acid transporter, SLC6A14 (also known as ATB<sup>0,+</sup>), with regard to its relevance to specific diseases, including cancer, and the molecular mechanisms underlying the disease-related alterations in the expression of the transporter.
|
29204754 |
2017 |
Pancreatic carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The expression of amino acid transporters in pancreatic cancer was analysed using publicly available microarray datasets, and the findings with the transporter SLC6A14 were validated by mRNA and protein analysis.
|
27747870 |
2016 |
Pancreatic Ductal Adenocarcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Transcriptomic and Immunohistochemical Profiling of SLC6A14 in Pancreatic Ductal Adenocarcinoma.
|
26106611 |
2015 |